| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- NCT07137416 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Mi NCT07191717 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Canc NCT07500129 | Atlas University | — |
| Not Yet Recruiting | Individual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France. NCT07475325 | University Hospital, Lille | — |
| Recruiting | Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer NCT07289282 | Atlas University | — |
| Recruiting | Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC NCT07080944 | European Institute of Oncology | N/A |
| Withdrawn | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Tre NCT06590558 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | NearWave Optical Molecular Monitoring NCT06744465 | Indiana University | N/A |
| Not Yet Recruiting | Application of Single-Port Robot-Assisted Breast-Conserving Surgery Via Axillary Approach for Breast Cancer. NCT06738654 | Xu Yan | N/A |
| Recruiting | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemother NCT06763328 | City of Hope Medical Center | Phase 3 |
| Recruiting | Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer NCT05406232 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer NCT05710328 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Active Not Recruiting | Metformin and Nightly Fasting in Women With Early Breast Cancer NCT05023967 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast NCT05545150 | Northwestern University | Phase 2 |
| Recruiting | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negati NCT05464810 | Emory University | EARLY_Phase 1 |
| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Recruiting | Neoadjuvant Breast Cancer Time Restricted Eating NCT05327608 | Thomas Jefferson University | N/A |
| Terminated | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer NCT05447910 | Mayo Clinic | — |
| Active Not Recruiting | Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast NCT05340673 | City of Hope Medical Center | Phase 1 |
| Recruiting | Breast Cancer Survivorship Biorepository NCT05786664 | University of Southern California | — |
| Recruiting | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer NCT05319873 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV T NCT05177796 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The NCT04667481 | University of Washington | N/A |
| Completed | An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors NCT05012176 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Recruiting | Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer NCT04959474 | Thomas Jefferson University | N/A |
| Active Not Recruiting | Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer NCT04897009 | Mayo Clinic | — |
| Active Not Recruiting | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases NCT04647916 | SWOG Cancer Research Network | Phase 2 |
| Completed | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast C NCT04481113 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer NCT04871516 | Rutgers, The State University of New Jersey | N/A |
| Completed | Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer NCT05071677 | M.D. Anderson Cancer Center | — |
| Recruiting | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients NCT03606967 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion NCT05036083 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Br NCT04457596 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiv NCT04379570 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Recruiting | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer NCT04521764 | Mayo Clinic | Phase 1 |
| Terminated | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer NCT04139993 | Mayo Clinic | Phase 1 |
| Completed | Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer NCT04294225 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Thera NCT04266249 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Active Not Recruiting | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast NCT04009044 | Northwestern University | Phase 2 |
| Completed | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer NCT03554044 | University of California, San Francisco | Phase 1 |
| Terminated | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Ca NCT03979508 | Mayo Clinic | Phase 2 |
| Suspended | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer NCT03737695 | Mayo Clinic | — |
| Completed | Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer NCT04087057 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer NCT04001829 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer NCT04022772 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectabl NCT03971409 | Laura Huppert, MD, BA | Phase 2 |
| Recruiting | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cance NCT04169542 | M.D. Anderson Cancer Center | — |
| Terminated | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases NCT03796273 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Completed | A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity NCT03789877 | Roswell Park Cancer Institute | N/A |
| Withdrawn | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors NCT02856503 | Eli Avisar, MD | Phase 1 / Phase 2 |
| Withdrawn | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer NCT03238703 | Fred Hutchinson Cancer Center | Phase 4 |
| Completed | Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer NCT03323658 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer NCT03518242 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer NCT02876640 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa B NCT03414970 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer NCT03454529 | Michael Simon | Phase 2 |
| Completed | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer NCT03345420 | University of Utah | Phase 2 |
| Active Not Recruiting | Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Can NCT03359954 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Exercise in Improving Health and Quality of Life in Breast Cancer Survivors NCT03679559 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnos NCT02883062 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage NCT03128619 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resi NCT02860000 | Mayo Clinic | Phase 2 |
| Completed | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer NCT02779855 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Recruiting | Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With N NCT02918474 | M.D. Anderson Cancer Center | N/A |
| Completed | Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery NCT03188393 | NRG Oncology | Phase 2 |
| Suspended | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer NCT03077841 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer NCT02912312 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca NCT02957968 | Virginia Commonwealth University | Phase 2 |
| Recruiting | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuva NCT02945579 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer NCT02954874 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Brea NCT02876107 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Tr NCT02689427 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT02453620 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer NCT02530489 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicte NCT02456857 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer NCT02276443 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy NCT02445391 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Active Not Recruiting | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer NCT02515110 | Virginia Commonwealth University | N/A |
| Completed | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Earl NCT02526498 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer NCT02282345 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer NCT02370277 | University of Southern California | — |
| Suspended | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage III NCT02037529 | Academic and Community Cancer Research United | Phase 3 |
| Completed | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01964924 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Broccoli Sprout Extract in Treating Patients With Breast Cancer NCT01753908 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors NCT01849250 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck C NCT01846091 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Brea NCT01750073 | University of Nebraska | Phase 2 |
| Completed | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Pa NCT01622868 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relaps NCT01434303 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer NCT01334021 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal NCT01344031 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients Wit NCT01272037 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carci NCT01266642 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer NCT01245712 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Ca NCT00877500 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breas NCT00601900 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer NCT00429182 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With NCT00477100 | M.D. Anderson Cancer Center | — |
| Terminated | Capecitabine in Women With Operable Breast Cancer NCT00148720 | Dana-Farber Cancer Institute | Phase 2 |